Skip to content

Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder

Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06441864
Enrollment
20
Registered
2024-06-04
Start date
2024-07-15
Completion date
2026-12-01
Last updated
2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nightmare, Nightmare Disorder With Associated Other Sleep Disorder, REM Sleep Behavior Disorder

Keywords

Imagery Rehearsal Therapy, Cognitive Behavioral Therapy for Nightmares

Brief summary

The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD). People with RBD will be enrolled in the study along with their family members (a partner or other family member residing in the same home). All participants will receive the treatment via videoconference and will complete 2 assessments. Participants with RBD will attend 7 sessions, and their family members will attend 2 of those sessions with them.

Interventions

BEHAVIORALCognitive Behavioral Therapy for Nightmares

The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. Family members will attend 2 of the 7 treatment sessions. During the sessions, participants will learn techniques for managing and changing nightmares.

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Multiple baseline single case experimental design

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of isolated RBD or RBD secondary to neurodegenerative disease * Age 18 or older * Speak, read, and write English * Live in the United States * Nightmare frequency ≥3 times per week * Disturbing Dream and Nightmare Severity Index score indicative of nightmare disorder * Sleep, neurological, and psychiatric medications stable for at least 1 month and willing to keep medications stable through the course of the study * Live with a family member who is willing to participate in the study

Exclusion criteria

* Possible dementia * Narcolepsy * Posttraumatic stress disorder * Previous behavioral treatment for nightmares * Currently engaged in sleep- or trauma-focused psychotherapy * Taking a medication that could cause RBD, if the medication was started prior to onset of RBD symptoms Inclusion Criteria (Family Members): * Live with a family member who meets all of the above criteria * Age 18 or older * Speak, read, and write English * Live in the United States

Design outcomes

Primary

MeasureTime frameDescription
Disturbing Dream and Nightmare Severity Index (DDNSI)Baseline and posttreatmentThe DDNSI is a questionnaire which measures the severity of nightmares.
Nightmare frequency (sleep diary)Baseline and posttreatmentThe number of nightmares experienced each day will be collected on daily sleep diaries completed during each assessment period.

Countries

United States

Contacts

CONTACTJennifer Mundt, PhD
RBDstudy@utah.edu801-646-8287

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026